Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other financing activities (2018 - 2021)

ImmunityBio (IBRX) has disclosed Other financing activities for 4 consecutive years, with -$2.6 million as the latest value for Q4 2021.

  • Quarterly Other financing activities changed N/A to -$2.6 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2022, down 182.86% year-over-year, with the annual reading at $1.4 million for FY2021, N/A changed from the prior year.
  • Other financing activities for Q4 2021 was -$2.6 million at ImmunityBio, down from $1.4 million in the prior quarter.
  • The five-year high for Other financing activities was $2.6 million in Q1 2021, with the low at -$2.6 million in Q4 2021.
  • Average Other financing activities over 4 years is $162111.1, with a median of $40000.0 recorded in 2019.
  • The sharpest move saw Other financing activities crashed 507.5% in 2020, then soared 2033.33% in 2021.
  • Over 4 years, Other financing activities stood at $50000.0 in 2018, then tumbled by 232.0% to -$66000.0 in 2019, then tumbled by 146.97% to -$163000.0 in 2020, then crashed by 1488.34% to -$2.6 million in 2021.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$2.6 million, $1.4 million, and $2.6 million for Q4 2021, Q3 2021, and Q1 2021 respectively.